Epidemiology

You have full text access to this OnlineOpen article

Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort

  1. Agnès Fournier1,
  2. Franco Berrino3,
  3. Elio Riboli2,
  4. Valérie Avenel1,
  5. Françoise Clavel-Chapelon1,†,*

Article first published online: 18 NOV 2004

DOI: 10.1002/ijc.20710

Issue

International Journal of Cancer

International Journal of Cancer

Volume 114, Issue 3, pages 448–454, 10 April 2005

Additional Information

How to Cite

Fournier, A., Berrino, F., Riboli, E., Avenel, V. and Clavel-Chapelon, F. (2005), Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int. J. Cancer, 114: 448–454. doi: 10.1002/ijc.20710

Author Information

  1. 1

    Equipe E3N, Institut National de la Santé et de la Recherche Médicale (INSERM), Villejuif, France

  2. 2

    Unit of Nutrition and Cancer, International Agency for Research on Cancer (IARC-WHO), Lyon, France

  3. 3

    Department of Preventive and Predictive Medicine, Istituto Nazionale Tumori, Milan, Italy

  1. †

    Fax: +33-1-42-11-40-00

*Equipe E3N, INSERM, Institut Gustave-Roussy, 94805, Villejuif, France

Publication History

  1. Issue published online: 8 FEB 2005
  2. Article first published online: 18 NOV 2004
  3. Manuscript Accepted: 12 AUG 2004
  4. Manuscript Received: 12 MAY 2004

Funded by

  • French League against Cancer
  • European Community
  • 3M Company
  • Mutuelle Générale de l'Education Nationale
  • Institut Gustave-Roussy
  • Institut National de la Santé et de la Recherche Médicale

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (96K)

References

  • 1
    Writing Group for the Women's Health Initiative. Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women. Principal results from the Women's Health Initiative Randomized Controlled Trial. JAMA 2002; 288: 321–33.
  • 2
    Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D, Rodabough RJ, Gilligan MA, Cyr MG, Thomson CA, Khandekar J, Petrovitch H, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 2003; 289: 3243–53.
  • 3
    Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003; 362: 419–27.
  • 4
    Hersh AL, Stefanick ML, Stafford RS. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA 2004; 291: 47–53.
  • 5
    Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004; 291: 1701–12.
  • 6
    Clavel-Chapelon F, and the E3N-EPIC Group. Differential effects of reproductive factors on the risk of pre- and post-menopausal breast cancer. Results from a large cohort of French women. Br J Cancer 2002; 4: 723–7.
  • 7
    Riboli E. Nutrition and cancer: background and rationale of the European Prospective Investigation into Cancer and Nutrition (EPIC). Annals of Oncology 1992; 3: 783–91.
  • 8
    Ross RK, Paganini-Hill A, Wan PC, Pike MC. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst 2000; 92: 328–32.
  • 9
    Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R. Menopausal Estrogen and Estrogen-Progestin Replacement Therapy and Breast Cancer Risk. JAMA 2000; 283: 485–91.
  • 10
    Newcomb PA, Titus-Ernstoff L, Egan KM, Trentham-Dietz A, Baron JA, Storer BE, Willett WC, Stampfer MJ. Postmenopausal estrogen and progestin use in relation to breast cancer risk. Cancer Epidemiol Biomarkers Prev 2002; 11: 593–600.
  • 11
    Porch JV, Lee IM, Cook NR, Rexrode KM, Buring JE. Estrogen-progestin replacement therapy and breast cancer risk: the Women's Health Study (United States). Cancer Causes Control 2002; 13: 847–54.
  • 12
    Weiss LK, Burkman RT, Cushing-Haugen KL, Voigt LF, Simon MS, Daling JR, Norman SA, Bernstein L, Ursin G, Marchbanks PA, Strom BL, Berlin JA, et al. Hormone replacement therapy regimens and breast cancer risk. Obstet Gynecol 2002; 100: 1148–58.
  • 13
    Li CI, Malone KE, Porter PL, Weiss NS, Tang M-TC, Cushing-Haugen KL, Daling JR. Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. JAMA 2003; 289: 3254–63.
  • 14
    Magnusson C, Baron JA, Correia N, Bergstrom R, Adami H-O, Persson I. Breast-cancer risk following long-term oestrogen- and oestrogen-progestin-replacement therapy. Int J Cancer 1999; 81: 339–44.
    Direct Link:
  • 15
    Persson I, Weiderpass E, Bergkvist L, Bergstrom R, Schairer C. Risks of breast and endometrial cancer after estrogen and estrogen-progestin replacement. Cancer Causes Control 1999; 10: 253–60.
  • 16
    Olsson HK, Ingvar C, Bladstrom A. Hormone replacement therapy containing progestins and given continuously increases breast carcinoma risk in Sweden. Cancer 2003; 97: 1387–92.
    Direct Link:
  • 17
    Jernstrom H, Bendahl P-O, Lidfeldt J, Nerbrand C, Agardh C-D, Samsioe G. A prospective study of different types of hormone replacement therapy use and the risk of subsequent breast cancer: the women's health in the Lund area (WHILA) study (Sweden). Cancer Causes Control 2003; 14: 673–680.
  • 18
    Stahlberg C, Pedersen AT, Lynge E, Andersen ZJ, Keiding N, Hundrup YA, Obel EB, Ottesen B. Increased risk of breast cancer following different regimens of hormone replacement therapy frequently used in Europe. Int J Cancer 2004; 109: 721–727.
    Direct Link:
  • 19
    Key TJ, Pike MC. The role of oestrogens and progestagens in the epidemiology and prevention of breast cancer. Eur J Cancer Clin Oncol 1988; 24: 29–43.
  • 20
    Fergusson DJ, Anderson TJ. Morphological evaluation of cell turnover in relation to menstrual cycle in the “resting” human breast. Br J Cancer 1981; 44: 177–81.
  • 21
    Going JJ, Anderson TJ, Battersby S, MacIntyre CC. Proliferative and secretory activity in human breast during natural and artificial menstrual cycles. Am J Pathol 1988; 130: 193–204.
  • 22
    Potten CS, Watson RJ, Williams GT, Tickle S, Roberts SA, Harris M, Howell A. The effect of age and menstrual cycle upon proliferative activity of the normal human breast. Br J Cancer 1988; 58: 163–70.
  • 23
    McManus MJ, Welsch CW. The effect of estrogen, progesterone, thyroxine, and human placental lactogen on DNA synthesis of human breast ductal epithelium maintained in athymic nude mice. Cancer 1984; 54: 1920–7.
    Direct Link:
  • 24
    Groshong SD, Owen GI, Grimison B, Schauer IE, Todd MC, Langan TA, Sclafani RA, Lange CA, Horwitz KB. Biphasic regulation of breast cancer cell growth by progesterone: role of the cyclin-dependant kinase inhibitors, p21 and p27kip1. Mol Endocrinol 1997; 11: 1593–1607.
  • 25
    Chang KJ, Fournier S, Lee Ti TY, de Lignières B, Linares G. Influence of percutaneous administration of estradiol and progesterone on human breast epithelial cell cycle in vivo. Fertil Steril 1995; 63: 785–91.
  • 26
    Foidart JM, Colin C, Denoo X, Desreux J, Beliard A, Fournier S, de Lignieres B. Estradiol and progesterone regulate the proliferation of human breast epithelial cells. Fertil Steril 1998; 69: 963–9.
  • 27
    Greendale GA, Reboussin BA, Slone S, Wasilauskas C, Pike MC, Ursin G. Postmenopausal hormone therapy and change in mammographic density. J Natl Cancer Inst 2003; 95: 30–7.
  • 28
    Colditz GA, Hankinson SE, Hunter DJ, Willett WC, Manson JE, Stampfer MJ, Hennekens C, Rosner B, Speizer FE. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995; 332: 1589–93.
  • 29
    Persson I, Thurfjell E, Bergström R, Holmberg L. Hormone replacement therapy and the risk of breast cancer: nested case-control study in a cohort of Swedish women attending mammography screening. Int J Cancer 1997; 72: 758–61.
    Direct Link:
  • 30
    Chen CL, Weiss NS, Newcomb P, Barlow W, White E. Hormone replacement therapy in relation to breast cancer. JAMA 2002; 287: 734–41.
  • 31
    Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet 1997; 350: 1047–59.
  • 32
    Campagnoli C, Ambroggio S, Biglia N, Sismondi P. Conjugated estrogens and breast cancer risk. Gynecol Endocrinol 1999; 13: 13–9.
  • 33
    Campagnoli C, Biglia N, Peris C, Sismondi P. Potential impact on breast cancer risk of circulating insulin-like growth factor I modifications induced by oral HRT in menopause. Gynecol Endocrinol 1995; 9: 67–74.
  • 34
    Bellantoni MF, Vittone J, Campfield AT, Bass KM, Harman SM, Blackman MR. Effects of oral versus transdermal estrogen on the growth hormone/insulin-like growth factor I axis in younger and older postmenopausal women: a clinical research center study. J Clin Endocrinol Metabol 1996; 81: 2848–53.
  • 35
    Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, Rosner B, Speizer FE, Pollak M. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 1998; 351: 1393–6.
  • 36
    Toniolo P, Bruning PF, Akhmedkhanov A, Bonfrer JM, Koenig KL, Lukanova A, Shore RE, Zeleniuch-Jacquotte A. Serum insulin-like growth factor-I and breast cancer. Int J Cancer 2000; 88: 828–32.
    Direct Link:
  • 37
    Muti P, Quattrin T, Grant BJ, Krogh V, Micheli A, Schunemann HJ, Ram M, Freudenheim JL, Sieri S, Trevisan M, Berrino F. Fasting glucose is a risk factor for breast cancer: a prospective study. Cancer Epidemiol Biomarkers Prev 2002; 11: 1361–8.
  • 38
    Haftenberger M, Lahmann PH, Panico S, Gonzalez CA, Seidell JC, Boeing H, Giurdanella MC, Krogh V, Bueno-de-Mesquita HB, Peeters PH, Skeie G, Hjartaker A, et al. Overweight, obesity and fat distribution in 50- to 64-year-old participants in the European Prospective Investigation into Cancer and Nutrition (EPIC). Public Health Nutr 2002; 5: 1147–62.
  • 39
    Pike MC, Ross RK, Spicer DV. Problems involved in including women with simple hysterectomy in epidemiologic studies measuring the effects of hormone replacement therapy on breast cancer risk. Am J Epidemiol 1998; 147: 718–721.
  • 40
    Rockhill B, Colditz GA, Rosner B. Bias in breast cancer analyses due to error in age at menopause. Am J Epidemiol 2000; 151: 404–8.
  • 41
    Banks E. Hormone replacement therapy and the sensitivity and specificity of breast cancer screening: a review. J Med Screen 2001; 8: 29–34.
  • 42
    Séradour B, Estève J, Heid P, Jacquemier J. Hormone replacement therapy and screening mammography: analysis of the results in the Bouches du Rhône programme. J Med Screen 1999; 6: 99–102.
  • 43
    Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemol 2003; 158: 915–20.
View Full Article (HTML) Get PDF (96K)